Nuvation Bio Inc.

NUVB

NYSE

Healthcare

Biotechnology

New York City, NY, US273 employeesnuvationbio.com

$4.46

-0.04(-1.00%)

Mkt Cap $1.5B

$1.66

$9.54

52-Week Range

At A Glance

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.

Revenue is primarily driven by License (44%) and Product Revenue (24.8%).

Most recently: . RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 2, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ende (2026-03-02).

$1.5B

Market Cap

$63M

Revenue

-$206M

Net Income

Employees273

Fundamentals

How The Business Makes Money

Revenue by Segment

License44%($48M)

Product Revenue24.8%($27M)

Product22.5%($25M)

Research And Development Service Revenue7.7%($8M)

Royalty Revenue1%($1M)

Revenue by Geography

JP45.2%($60M)

US36.9%($49M)

CN17.9%($24M)

Activity

What Changed Recently

Financial Results

Mar 1, 2026

. RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 2, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ende

Material Agreement+3 More

Jan 11, 2026

Entry into a Material Definitive Agreement. On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Lice

Peer Companies

Company	Price	Change	Market Cap	P/E
EWTXEdgewise Therapeutics, In...	$33.37	+0.69%	$3.6B	-18.3
GPCRStructure Therapeutics In...	$53.27	+6.18%	$3.1B	-20.6
VERAVera Therapeutics, Inc.	$40.82	+0.79%	$2.9B	-8.7
AUPHAurinia Pharmaceuticals I...	$15.64	+1.13%	$2.1B	6.8
CLDXCelldex Therapeutics, Inc...	$31.00	-0.85%	$2.1B	-8.2
OCULOcular Therapeutix, Inc.	$8.48	+1.86%	$1.8B	-6.8
VRDNViridian Therapeutics, In...	$18.82	-1.70%	$1.6B	-6.8
ABCLAbCellera Biologics Inc.	$3.54	+0.71%	$1.1B	-6.9

Analyst View

Company Profile

CIK0001811063

ISINUS67080N1019

CUSIP67080N101

Phone332 208 6102

Address1500 Broadway, New York City, NY, 10036, US

SEC EDGAR